FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211062034> ?p ?o ?g. }

• W3211062034 endingPage "e1097" @default.
• W3211062034 startingPage "e1097" @default.
• W3211062034 abstract "Progressive multifocal leukoencephalopathy (PML) is a disabling neurologic disorder resulting from the infection of the CNS by JC polyomavirus in immunocompromised individuals. For the last 2 decades, increasing use of immunotherapies leads to iatrogenic PML. Iatrogenic PML is often associated with signs of inflammation at onset (inflammatory PML) and/or after treatment withdrawal immune reconstitution inflammatory syndrome (PML-IRIS). Although immune reconstitution is a key element for viral clearance, it may also be harmful and induce clinical worsening. A C-C chemokine receptor type 5 (CCR5) antagonist (maraviroc) has been proposed to prevent and/or limit the deleterious immune responses underlying PML-IRIS. However, the data to support its use remain scarce and disputed.We conducted a multicenter retrospective cohort study at 8 university hospitals in France and Switzerland by collecting clinical, biological, and radiologic data of patients who developed inflammatory PML (iPML) or PML-IRIS related to immunosuppressive therapies used for chronic inflammatory diseases between 2010 and 2020. We added to this cohort, a meta-analysis of individual case reports of patients with iPML/PML-IRIS treated with maraviroc published up to 2021.Overall, 27 cases were identified in the cohort and 9 from the literature. Among them, 27 met the inclusion criteria: 16 treated with maraviroc and 11 with standard of care (including corticosteroids use). Most cases were related to MS (92.6%) and natalizumab (88%). Inflammatory features (iPML) were present at onset in 12 patients (44.4%), and most patients (92.6%) received corticosteroids within the course of PML. Aggravation due to PML-IRIS was not prevented by maraviroc compared with patients who received only corticosteroids (adjusted odds ratio: 0.408, 95% CI: 0.06-2.63). Similarly, maraviroc did not influence time to clinical worsening due to PML-IRIS (adjusted hazard ratio = 0.529, 95% CI: 0.14-2.0) or disability at the last follow-up (adjusted odds ratio: 2, 95% CI: 0.23-17.3).The use of CCR5 blockade did not help to keep deleterious immune reconstitution in check even when associated with corticosteroids. Despite maraviroc's reassuring safety profile, this study does not support its use in iPML/PML-IRIS.This study provides Class IV evidence showing that adding maraviroc to the management of iatrogenic iPML/PML-IRIS does not improve the outcome." @default.
• W3211062034 created "2021-11-08" @default.
• W3211062034 creator A5011626280 @default.
• W3211062034 creator A5019260960 @default.
• W3211062034 creator A5019857973 @default.
• W3211062034 creator A5023099061 @default.
• W3211062034 creator A5025519386 @default.
• W3211062034 creator A5032036144 @default.
• W3211062034 creator A5038981809 @default.
• W3211062034 creator A5045540371 @default.
• W3211062034 creator A5047268222 @default.
• W3211062034 creator A5057598570 @default.
• W3211062034 creator A5069373819 @default.
• W3211062034 creator A5075371427 @default.
• W3211062034 creator A5082463455 @default.
• W3211062034 date "2021-11-02" @default.
• W3211062034 modified "2023-10-13" @default.
• W3211062034 title "CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments" @default.
• W3211062034 cites W1547213639 @default.
• W3211062034 cites W1968419120 @default.
• W3211062034 cites W1980076690 @default.
• W3211062034 cites W1984207776 @default.
• W3211062034 cites W1986802107 @default.
• W3211062034 cites W1997327340 @default.
• W3211062034 cites W2062723067 @default.
• W3211062034 cites W2073728662 @default.
• W3211062034 cites W2094159877 @default.
• W3211062034 cites W2099815357 @default.
• W3211062034 cites W2106747769 @default.
• W3211062034 cites W2145556928 @default.
• W3211062034 cites W2153562194 @default.
• W3211062034 cites W2153960708 @default.
• W3211062034 cites W2253819451 @default.
• W3211062034 cites W2464861151 @default.
• W3211062034 cites W2587232121 @default.
• W3211062034 cites W2587755004 @default.
• W3211062034 cites W2612339088 @default.
• W3211062034 cites W2760389596 @default.
• W3211062034 cites W2765619934 @default.
• W3211062034 cites W2770673751 @default.
• W3211062034 cites W2781511522 @default.
• W3211062034 cites W2783950346 @default.
• W3211062034 cites W2914801145 @default.
• W3211062034 cites W3006076563 @default.
• W3211062034 cites W3101882702 @default.
• W3211062034 doi "https://doi.org/10.1212/nxi.0000000000001097" @default.
• W3211062034 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8564863" @default.
• W3211062034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34728496" @default.
• W3211062034 hasPublicationYear "2021" @default.
• W3211062034 type Work @default.
• W3211062034 sameAs 3211062034 @default.
• W3211062034 citedByCount "7" @default.
• W3211062034 countsByYear W32110620342022 @default.
• W3211062034 countsByYear W32110620342023 @default.
• W3211062034 crossrefType "journal-article" @default.
• W3211062034 hasAuthorship W3211062034A5011626280 @default.
• W3211062034 hasAuthorship W3211062034A5019260960 @default.
• W3211062034 hasAuthorship W3211062034A5019857973 @default.
• W3211062034 hasAuthorship W3211062034A5023099061 @default.
• W3211062034 hasAuthorship W3211062034A5025519386 @default.
• W3211062034 hasAuthorship W3211062034A5032036144 @default.
• W3211062034 hasAuthorship W3211062034A5038981809 @default.
• W3211062034 hasAuthorship W3211062034A5045540371 @default.
• W3211062034 hasAuthorship W3211062034A5047268222 @default.
• W3211062034 hasAuthorship W3211062034A5057598570 @default.
• W3211062034 hasAuthorship W3211062034A5069373819 @default.
• W3211062034 hasAuthorship W3211062034A5075371427 @default.
• W3211062034 hasAuthorship W3211062034A5082463455 @default.
• W3211062034 hasBestOaLocation W32110620341 @default.
• W3211062034 hasConcept C126322002 @default.
• W3211062034 hasConcept C12823836 @default.
• W3211062034 hasConcept C13373296 @default.
• W3211062034 hasConcept C142462285 @default.
• W3211062034 hasConcept C203014093 @default.
• W3211062034 hasConcept C2522874641 @default.
• W3211062034 hasConcept C2776914184 @default.
• W3211062034 hasConcept C2778899366 @default.
• W3211062034 hasConcept C2779778235 @default.
• W3211062034 hasConcept C2780644213 @default.
• W3211062034 hasConcept C2993143319 @default.
• W3211062034 hasConcept C3013748606 @default.
• W3211062034 hasConcept C37044404 @default.
• W3211062034 hasConcept C71924100 @default.
• W3211062034 hasConcept C72563966 @default.
• W3211062034 hasConceptScore W3211062034C126322002 @default.
• W3211062034 hasConceptScore W3211062034C12823836 @default.
• W3211062034 hasConceptScore W3211062034C13373296 @default.
• W3211062034 hasConceptScore W3211062034C142462285 @default.
• W3211062034 hasConceptScore W3211062034C203014093 @default.
• W3211062034 hasConceptScore W3211062034C2522874641 @default.
• W3211062034 hasConceptScore W3211062034C2776914184 @default.
• W3211062034 hasConceptScore W3211062034C2778899366 @default.
• W3211062034 hasConceptScore W3211062034C2779778235 @default.
• W3211062034 hasConceptScore W3211062034C2780644213 @default.
• W3211062034 hasConceptScore W3211062034C2993143319 @default.
• W3211062034 hasConceptScore W3211062034C3013748606 @default.
• W3211062034 hasConceptScore W3211062034C37044404 @default.
• W3211062034 hasConceptScore W3211062034C71924100 @default.

• next